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Cytolethal distending toxin (CDT), a genotoxin produced by Campylobacter jejuni, is
composed of three subunits: CdtA, CdtB, and CdtC. CdtB is a DNase that causes DNA
double-strand breaks (DSB) in the nucleus resulting in cell cycle arrest at the G2/M
stage and apoptosis. CdtA and CdtC bind to cholesterol-rich microdomains on the
cytoplasmic membrane, a process required for the delivery of CdtB to cells. Although
a unique motif associated with cholesterol-binding activity has been identified in other
pathogens, the mechanism underlying the interaction between the CdtA and CdtC
subunits and membrane cholesterol remains unclear. Also, the processes of cell uptake
and delivery of CdtB in host cells and the translocation of CdtB into the nucleus are only
partially understood. In this review, we focus on the underlying relationship among CDT,
membrane cholesterol, and the intracellular trafficking pathway as a unique mechanism
for C. jejuni-induced pathogenesis. Moreover, we discuss the clinical aspects of a
possible therapeutic application of CDT in cancer therapy. Understanding the molecular
mechanism of CDT-host interactions may provide insights into novel strategies to control
C. jejuni infection and the development of potential clinical applications of CDT.
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INTRODUCTION
Campylobacter jejuni, a gram-negative bacterium, is one of the most common causative agents of
food-borne infectious illnesses in humans (Butzler and Skirrow, 1979; Mead et al., 1999). Infection
by C. jejuni in humans usually occurs through the consumption of contaminated poultry products
(Corry and Atabay, 2001), and C. jejuni-associated enterocolitis is typically associated with a
local acute inflammatory response that involves intestinal tissue damage (Black et al., 1988). An
Lai et al. Biological Function of Cj-CDT
important C. jejuni virulence factor, cytolethal distending toxin
(CDT), has been characterized in detail (Lara-Tejero and Galan,
2000) and is thought to be associated with C. jejuni-induced
local acute inflammation involved in enterocolitis (Zheng et al.,
2008). Although CDT can be produced by various gram-
negative bacteria with certain diversity in genes, its ultimate
function resembles that of a genotoxin (Gargi et al., 2012). The
interactions between C. jejuni CDT (Cj-CDT) and membrane
cholesterol-rich microdomains and the role of cholesterol in the
Cj-CDT intoxication of host cells have recently been reported
(Lin et al., 2011). However, the molecular basis of Cj-CDT
association with the cell membrane and delivery of toxin
subunits into cells remains uncertain. This review provides an
overview of recent studies and advancements that address Cj-
CDT-cell interactions and intracellular trafficking pathways at the
molecular level. Additionally, we discuss several novel strategies
for developing CDT into a cancer therapeutic and its potential
clinical applications.
COMPOSITION AND FUNCTIONS OF
CJ-CDT
The discovery of Cj-CDT and subsequent reporting of its
biological function has continued for decades (Johnson and
Lior, 1988; Mizuno et al., 1994). Evidence demonstrated that
Cj-CDT comprises three protein subunits, Cj-CdtA, Cj-CdtB,
and Cj-CdtC, encoded by an operon composed of the genes
cdtA, cdtB, and cdtC (Pickett et al., 1996). Each cdt variant
contains a consensus ribosome-binding site and encodes protein
subunits with predicted molecular masses of 30,116, 28,989,
and 21,157 kDa, respectively (Pickett et al., 1996). Among
the three subunits, Cj-CdtA and Cj-CdtC are required for
assembling a tripartite complex with Cj-CdtB for holotoxin
activity (Lara-Tejero and Galan, 2001) and binding to the
plasma membrane of cells (Bag et al., 1993). Cj-CdtB does
not bind to the cell membrane, but rather possesses type I
deoxyribonuclease (DNase I) activity, which causes DNA double-
strand breakage (DSB) and leads to cell-cycle arrest at the
G2/M phase, thereby inducing cell distention and resulting in
senescence or target-cell death (Whitehouse et al., 1998; Lara-
Tejero and Galan, 2000). In addition to its DNase I activity,
the enzymatic subunit Aa-CdtB has phosphatidylinositol 3-4-5
trisphosphate (PIP3) phosphatase activity that induces apoptosis
in T cells (Shenker et al., 2007). Structural and sequence
analyses of Aa-CdtB indicated that it shared homology with
inositol polyphosphate 5-phosphatase (Shenker et al., 2007).
Moreover, mutation of Aa-CdtB reduces its phosphatase activity,
abolishes CDT-induced G2/M arrest, and decreases DNase I-
like activity. The phosphatase activity of CdtB may target Wee1
kinase or Cdc25 phosphatase that consequently alter cell cycle
regulatory networks (Pickett and Whitehouse, 1999). These
results are supported by a previous report which stated that
the catalytic residue in Aa-CdtB possesses both DNase I and
phosphatase activities (Dlakic, 2001). However, the phosphatase
activity of Cj-CdtB has not yet been reported (Gargi et al.,
2012).
The intoxication of lymphocytes by Aa-CDT results in PIP3
depletion and perturbation of phosphatidylinositol-3-kinase (PI-
3K)/PIP3/Akt signaling concomitant with decreases in GSK3β
phosphorylation (Shenker et al., 2016). Moreover, blockade of
PI-3K signaling by Aa-CDT induces the production of pro-
inflammatory cytokines such as IL-1β, TNFα, and IL-6 by
macrophages (Shenker et al., 2014). These results indicate
that CDT functions as an immune modulator. Similar results
were found in a study showed that Cj-CDT induces IL-8
production and promotes chemotaxis by leukocytes, therefore
induces inflammation in host intestines (Hickey et al., 2000).
Moreover, C. jejuni with CDT enhances invasiveness in SCID
mouse tissues at a level higher than that in cdtB mutants
(Purdy et al., 2000). An NF-κB-deficient mouse infection model
has confirmed the critical role of Cj-CDT in bacteria-inducing
inflammatory responses and the contribution of Cj-CDT to
persistent bacterial infection in hosts (Fox et al., 2004). Although
its exact function in C. jejuni-induced pathogenesis has not
been fully demonstrated, Cj-CDT definitely possesses critical
roles in the invasiveness and modulation of immune response.
Similar to Cj-CDT, a variety of pathogenic gram-negative
bacteria have been identified as possessing CDT, including
Aggregatibacter actinomycetemcomitans (Aa-CDT) (Ohara et al.,
2004), Escherichia coli (Ec-CDT) (Johnson and Lior, 1988),
Haemophilus ducreyi (Hd-CDT) (Cope et al., 1997),Haemophilus
parasuis (Hp-CDT) (Zhang et al., 2012), Helicobacter hepaticus
(Hh-CDT) (Young et al., 2000), and Shigella dysenteriae (Sd-
CDT) (Okuda et al., 1995).
BINDING OF CJ-CDTA/-CDTC TO LIPID
RAFTS
CdtA and CdtC serve as carriers for delivering the active
subunit, CdtB, into host cells (Nesic and Stebbins, 2005). CdtB
is subsequently internalized, while CdtA and CdtC remain
associated with the membrane receptor (Lee et al., 2003). The
crystal structure of Hd-CDT revealed that CdtA and CdtC adopt
lectin-type structures that are homologous to the plant toxin
ricin (Nesic et al., 2004). The holotoxin contains two critical
binding elements: an aromatic patch in CdtA and a deep groove
at the interface of CdtA and CdtC (Nesic et al., 2004). Structure-
based mutagenesis demonstrated that mutations of the aromatic
patch and deep-groove residues inhibited toxin binding to the cell
surface, followed by attenuation of cell intoxication, indicating
that the two ricin-like lectin domains in CdtA and CdtC are
critical for CdtB binding (Nesic and Stebbins, 2005).
An analysis of Aa-CDT revealed that CdtA and CdtC were
both bound to the cell membrane and associated with lipid
rafts (Boesze-Battaglia et al., 2006), which contain abundant
cholesterol, phospholipids, and sphingolipids (Brown and
London, 1998). The structure of lipid rafts can be perturbed by
the cholesterol-depletion agent methyl-β-cyclodextrin (MβCD)
(Simons and Toomre, 2000). Treatment of cells with MβCD
attenuated the binding activity of Hd-CDT (Guerra et al., 2005)
and Aa-CDT (Boesze-Battaglia et al., 2006) to HeLa and Jurkat
cells, respectively, and reduced cell intoxication. Our previous
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report demonstrated that Cj-CDT associated with cholesterol-
rich microdomains in CHO-K1 cells in a modality similar to that
observed in Hd-CDT and Aa-CDT (Lin et al., 2011). The co-
localization of Aa-CDT and Cj-CDT with the lipid-raft markers
ganglioside GM1 and caveolin-1, respectively, was observed by
confocal microscopy (Boesze-Battaglia et al., 2006; Lin et al.,
2011). More recently, we showed that Cj-CDT administration
induced severe intestinal inflammation in mice fed a high-
cholesterol diet relative to control mice fed a normal diet,
demonstrating that cholesterol plays a crucial role in facilitating
CDT-induced pathological derangement in vivo (Lai et al., 2015).
These results collectively indicated that, similar to Hd-CDT and
Aa-CDT, cholesterol provides an essential ligand for Cj-CDT
binding to the cell membrane followed by host intoxication
(Figure 1), and that CdtA and CdtC contain a cholesterol-
binding motif.
CJ-CDTC CONTAINS A CONSERVED
CHOLESTEROL
RECOGNITION/INTERACTION MOTIF
A previous study reported the existence of a common cholesterol
recognition/interaction amino-acid consensus (CRAC) pattern
containing a conserved motif [L/V(X)1–5Y(X)1–5R/K] shown
to interact with cholesterol (Li and Papadopoulos, 1998). It
has been demonstrated that Aa-CdtC contains a CRAC region,
which contributes to the association between toxin subunits
and cholesterol (Boesze-Battaglia et al., 2009). The CRAC
motif also exists in the CdtC subunit of H. parasuis (Zhou
et al., 2012), and another study found CRAC-like region
77LPFGYVQFTNPK88 present in Cj-CdtC (Lin et al., 2011).
A structure-based simulation indicated that the 12-amino acid
residues of CRAC-like regions created a hydrophobic groove that
contributes to Cj-CdtC hydrophobic interactions and hydrogen
bonding with cholesterol (Lai et al., 2013). Mutation within the
CRAC-like region (CdtCY81P) reduced Cj-CDT binding to cells,
but did not disrupt formation of the holotoxin complex (Lai et al.,
2013). These reports were in agreement with studies of Aa-CdtC
and Hp-CdtC (Boesze-Battaglia et al., 2009; Zhou et al., 2012),
establishing that the CRAC-like region of Cj-CdtC plays a critical
role in CDT-holotoxin binding to membrane cholesterol, but not
in intermolecular interactions between each toxin subunit.
The results of a recent report showed that CdtA and CdtC
derived from E. coli and H. ducreyi likely interact with distinct
receptors on the cell surface and are independently sufficient
to support CdtB-mediated cytotoxicity (Dixon et al., 2015).
Depletion of cholesterol by MβCD reduces intoxication by Ec-
CdtAB and Ec-CDT holotoxin, which suggests that Ec-CdtA
can interact with cholesterol or a component(s) in lipid rafts to
promote efficient intoxication (Dixon et al., 2015). This finding
is similar to that of our previous study, which showed that
FIGURE 1 | CDT cellular intoxication pathway. CdtA and CdtC bind to cell membrane cholesterol-rich microdomains and facilitate CdtB entry into cells through
clathrin-coated pit endocytosis. Following internalization, CdtB translocates to the cytosol and may undergo retrograde trafficking from the Golgi complex into the
endoplasmic reticulum. The CdtB subunit ultimately translocates to the nucleus by virtue of a putative nuclear localization signal present in its amino-acid sequence.
Once in the nucleus, CdtB induces DNA double-strand breaks, which lead to cell-cycle arrest.
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membrane cholesterol is critical for Cj-CdtA binding and Cj-
CDT intoxication in host cells (Lin et al., 2011). However, the
receptors (i.e., cholesterol or components of cholesterol-rich
microdomains) for Cj-CdtA require further confirmation.
Although the Cj-CdtC CRAC motif is important to holotoxin
binding to membrane cholesterol, the cell-binding activity
of a Cj-CdtC variant containing a mutation in this region
was not thoroughly impaired. This result indicated that Cj-
CdtC binding to the cell membrane was mediated by either
cholesterol or non-cholesterol receptors (Lai et al., 2013).
In a study of Aa-CDT, depletion of cellular cholesterol by
MβCD did not alter CDT-binding in CHO-K1 cells (Damek-
Poprawa et al., 2012). Interestingly, Cj-CDT intoxication of
CHO-K1 cells was unchanged following cholesterol loading;
however, it was enhanced following inhibition of N-linked
glycosylation (Eshraghi et al., 2010). It was reported that Ec-
CDT interaction with membrane glycoproteins in HeLa cells
involved N-linked, but not O-linked fucose (McSweeney and
Dreyfus, 2005). In addition, ganglioside GM3 served as a receptor
for Aa-CDT (Mise et al., 2005). Interestingly, inactivation of
sphingomyelin synthase 1 (SGMS1), which encodes an enzyme
for sphingomyelin biosynthesis, abolished CDT intoxication by
Aa-CDT, Cj-CDT, Ec-CDT, and Hd-CDT (Carette et al., 2011).
Although these reports provided some conflicting results, Cj-
CDT association with cholesterol and carbohydrates appears
crucial for toxin-related triggering of the molecular machinery
involving lipid rafts and enhancing the efficiency of toxin-related
activity in target cells.
DELIVERY OF CJ-CDT INTO CELLS
Several gram-negative bacteria employ outer-membrane vesicles
(OMVs) for delivering active proteins or toxins into host
cells (Kulp and Kuehn, 2010). CDT associated with OMVs
secreted from C. jejuni was first reported by Lindmark et al.
(2009). Immunogold-labeling electron microscopy revealed that
all three CDT subunits were tightly associated with OMVs,
which functioned as a route for C. jejuni delivery of toxins into
the cellular environment (Lindmark et al., 2009). Interactions
of OMVs with membrane rafts have been reported in some
bacterial pathogens (Kesty et al., 2004; Kaparakis et al.,
2010). For example, CDT-associated OMVs secreted by A.
actinomycetemcomitans can be delivered to the cytoplasm by
membrane fusion dependent upon lipid rafts (Rompikuntal et al.,
2012). Using confocal microscopy to track CdtB in cells treated
with A. actinomycetemcomitans OMVs, nuclear translocation
of the toxin-activating subunit was observed (Rompikuntal
et al., 2012). The internalized A. actinomycetemcomitans OMVs
then induced NOD1- and NOD2-dependent NF-κB activation
(Thay et al., 2014). Similarly, a study of C. jejuni revealed
that treatment of cells with MβCD partially inhibited OMV-
induced inflammation, indicating that membrane rafts provided
a certain role for C. jejuni OMV-mediated signal transduction
(Elmi et al., 2012). These findings suggest that OMV interactions
with lipid rafts may promote the delivery of Cj-CDT to target
cells and enhance the efficiency of cell intoxication. Further
investigations are needed to fully comprehend the extent to which
Cj-CDT-associated OMVs rely upon membrane rafts for cellular
internalization into the cytoplasm and nuclear translocation.
DOES CJ-CDTB BIND TO CHOLESTEROL?
Several reports indicated that CdtB alone binds to neither the cell
membrane nor lipid rafts (Lara-Tejero and Galan, 2000; Guerra
et al., 2005; Boesze-Battaglia et al., 2009). However, a recent study
revealed that Aa-CdtB is capable of binding to large unilamellar
vesicles containing cholesterol (Boesze-Battaglia et al., 2015).
The authors demonstrated that, similar to Aa-CdtC, Aa-CdtB
contains a CRAC motif that contributed to cholesterol binding
and was required for toxin internalization and subsequent
intoxication of both lymphocytes and macrophages (Boesze-
Battaglia et al., 2015). However, in our Cj-CdtB study, this
subunit was not observed interacting with membrane cholesterol
in the absence of associations with CdtA and/or CdtC (Lin et al.,
2011). Despite variations in the CdtB amino-acid sequence and
structural characteristics among bacterial pathogens, the residues
associated with DNase I and phosphatase activities are highly
conserved (Shenker et al., 2007; Jinadasa et al., 2011; Gargi et al.,
2012).
CJ-CDTB NUCLEAR TRANSLOCATION
Upon binding to lipid-membrane microdomains, CDT is
rapidly internalized by clathrin-dependent endocytosis,
which was found in H. ducreyi (Cortes-Bratti et al., 2000).
Subsequent nuclear translocation requires Hd-CDT transport
by a retrograde pathway from the trans-Golgi network (TGN)
to the endoplasmic reticulum (ER) (Guerra et al., 2005). This
modality is similar to other bacterial toxins secreted from
different pathogens, including the Shiga toxin (Sandvig et al.,
2010) and cholera toxin (Wernick et al., 2010), which are
transported through the TGN to the ER prior to entering
the cytosol. However, unlike other toxins, Hd-CDT does not
exploit the mechanism of ER-associated degradation (ERAD)
normally employed for translocation of misfolded proteins
from the ER to the cytosol for proteasomal degradation (Guerra
et al., 2009). Additionally, Hd-CdtB does not appear in the
cytosol of intoxicated cells, suggesting that Hd-CdtB may
translocate directly from the ER to the nucleus (Guerra et al.,
2009). Interestingly, a recent study demonstrated that three
important components of ERAD machinery, Derlin-2 (Derl2),
E3 ubiquitin-protein ligase (Hrd1), and the AAAATPase p97, are
required for cell intoxication by CDT (Eshraghi et al., 2014). The
authors also revealed that Derl2 deletion resulted in resistance to
CDT-induced cell death by Aa-CDT and Hd-CDT, suggesting
that the ERAD pathway is important for CDT retrotranslocation.
However, cells lacking Derl2 displayed only modest resistance to
Cj-CDT. Similar to Der2-deficient cells, cells deficient in Hrd1
were sensitive to Cj-CDT intoxication (Eshraghi et al., 2014).
These findings suggest that Cj-CDT evolves distinct strategies to
reach the host nucleus and harbors peculiar host requirements
that differ from those of other CDTs.
CdtB possesses a putative nuclear-localization signal (NLS)
that is critical for directing the toxin-activating subunit from
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the ER to the nucleus. By employing a domain-swapping
experiment with an SV40T NLS, which has demonstrated that
the Aa-CdtB subunit comprised two domains: an N-terminal
domain for nuclear transport and a C-terminal activation domain
(Nishikubo et al., 2003). McSweeney and Dreyfus demonstrated
that two potential NLS sequences are present in the C-terminal
region of Ec-CdtB-II (McSweeney and Dreyfus, 2004). In cells
transfected with an Ec-CdtB-II-NLS1 mutant and Ec-CdtB-II-
NLS1/2 double mutants, the intoxication effects of the subunits
were abolished. These findings revealed that the putative NLS
sequence(s) are important for CdtB intracellular trafficking and
translocation to the nucleus. However, the presence of the NLS
sequence(s) in Cj-CdtB has yet to be determined.
Although CDTs from pathogens other than C. jejuni are
capable of retrograde transport through the TGN to the ER
and ultimately into the nucleus, two critical issues have emerged
regarding intracellular Cj-CDT trafficking. First, Cj-CDT neither
relies on Derl2 nor requires Hrd1 for this activity (Eshraghi
et al., 2014). Second, there is no experimental evidence regarding
the role of NLS in Cj-CdtB. Future studies exploring specific
components of Cj-CDT that exploit the ERAD pathway may help
delineate the mechanism of Cj-CdtB nuclear translocation.
APPLICATION OF CDT IN CANCER
THERAPY
Multidrug resistance is among the most critical reasons for
treatment failure in cancer patients. One example of therapeutic
resistance involves the presence of a major molecular eﬄux
pump in cell membranes that enables cancer cells to bypass drug
toxicity or alter cellular processes between the cytoplasm and
the nucleus (Szakacs et al., 2006). It is reasonable to develop
effective bacterial toxins as potential alternatives to treating
refractory tumors, given that these toxins are easily obtained from
bacteria and the bacteria can efficiently gain access to target cells
through membrane-receptor internalization. Several bacterial
virulence factors have been applied in clinical settings for cancer
therapy, including the anthrax toxin from Bacillus anthracis (Liu
et al., 2000), diphtheria toxin from Corynebacterium diphtheriae
(Frankel et al., 2002), and Shiga toxin from S. dysenteriae and
E. coli (Ishitoya et al., 2004). These studies provide evidence
of the value in developing bacterial toxins as potential cancer
therapeutic agents.
CDT is capable of inducing cell-cycle arrest by activating
ataxia telangiectasia mutated (ATM)-dependent DNA-damage
checkpoint responses and DSBs, similar to pathways induced
by ionizing radiation (IR; Fahrer et al., 2014). Given this
CDT function as a radiomimetic agent, emerging and effective
therapeutic modalities have been tested as treatments for several
cancer types (Table 1). This idea was demonstrated in our
recent study where use of a combination of Cj-CDT and IR
dramatically increased the efficacy of radiotherapy in radio-
resistant prostate cancer cells (Lai et al., 2014a). Our results also
revealed that Cj-CDT enhanced radio-sensitization attributable
to the attenuation of DSB repair, long-term cell-cycle arrest in
G2/M phase, and activation of the apoptotic pathway, indicating
TABLE 1 | Use of bacterial CDT variants for the experimental treatment of
cancer.
Bacterium harboring CDT Cancer cell type References
A. actinomycetemcomitans Human gingival squamous
carcinomas
Iwanaga et al., 2007
Human head and neck
squamous cell carcinomas
Damek-Poprawa
et al., 2011
C. jejuni Human prostate cancer Lai et al., 2014a
Human gastric cancer Lai et al., 2014b
H. ducreyi Human cervical carcinoma Bachran et al., 2014
Human head and neck
squamous cell carcinomas
Bachran et al., 2014
Human colon carcinoma Bachran et al., 2014
Human lung carcinoma Bachran et al., 2014
that Cj-CDTmay be a potent therapeutic agent for radio-resistant
cancer. Another study described local delivery of an Aa-cdtB-
expressing plasmid into human gingival squamous carcinoma
by sonoporation inhibiting the growth of tumor cells (Iwanaga
et al., 2007). Moreover, a mutant Aa-CdtA variant conjugated
to an anti-human CD133-monoclonal antibody led the toxin
targeting to CD133+ head and neck squamous-cell carcinomas
(Damek-Poprawa et al., 2011). This study provided evidence
that genetically modified CDT could specifically target cancer
stem cells and inhibit growth. Another study utilized Hd-
CdtB fused with B. anthracis-toxin lethal factor to efficiently
deliver toxin to various human tumor-cell lines, resulting in
impressive anti-tumor effects in a murine experimental model
(Bachran et al., 2014). Additionally, our recent report showed
that replacing Cj-CdtA/-CdtC subunits with chitosan/heparin
nanoparticles and encapsulating CdtB achieved markedly
increased inhibition of gastric-cancer growth in vitro and in vivo
without intoxication of primary gastric-epithelial cells (Lai
et al., 2014b). This strategy (combination nanoparticle therapy)
resulted in significant anti-tumor activities. The advantages of
these strategies include avoidance of toxins poisoning normal
cells by preferentially killing cancer cells. Therefore, CDT
combined with multiple delivery approaches constitutes a
potential anticancer drug that should be considered for further
development.
UTILIZATION OF CDT IN CLINICAL
SETTINGS
FcεRI crosslinked with IgE activates PI-3K and generates PIP3,
which plays a critical role in the activation of mast cells and
degranulation, leading to allergic responses, and inflammation
(Tkaczyk and Gilfillan, 2001). Aa-CdtB possesses PIP3-like
activity and functions as an immunotoxin (Shenker et al., 2007).
By fusing Aa-CdtB with the IgE Fcε-binding region, PI-3K/PIP3
signaling is disturbed, thereby inhibiting mast-cell degranulation
(Shenker et al., 2010). These studies implicated CdtB as a
promising targeted therapeutic agent for mast-cell-mediated
diseases (Shenker et al., 2011). Unlike CdtB, the major functions
of the CdtA/CdtC subunits involve binding to cholesterol-rich
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microdomains in the plasma membrane. Formation of a Hd-
CdtA-CdtC noncovalent complex protected cells against CDT-
holotoxin-indued cell death (Deng and Hansen, 2003). One
potential explanation is that the Hd-CdtA-CdtC complex may
occupy the holotoxin-biding region, which prevents or delays
CDT-related cell death. Although the precisemechanism remains
unclear, this study revealed a possible application of CDT
subunits in the prevention of pathogenic infections requiring
membrane-associated lipid rafts.
CONCLUSIONS AND FUTURE
PERSPECTIVES
Recent studies have demonstrated that Cj-CdtA/-CdtC interacts
with membrane-associated lipid rafts, enabling the Cj-CdtB
subunit to cross the cell membrane, undergo intracellular
trafficking, and translocate to the nucleus. Several relevant
issues have emerged and require further exploration, including
(1) which molecule(s) in the lipid rafts serve as receptor(s)
for Cj-CdtA/CdtC binding; (2) is the CRAC motif present
in the Cj-CdtA subunit and what is its precise role in
cholesterol binding; (3) to what extent do Cj-CDT-associated
OMVs rely on membrane rafts for cellular internalization and
nuclear translocation; (4) does the Cj-CdtB subunit contain
an NLS sequence; and (5) does controlling cholesterol prevent
CDT intoxication in vivo. Despite the availability of genetic
information and experimental studies, the understanding of
Cj-CDT-associated activities at the molecular level remains
incomplete.
Current experimental and epidemiological studies support
critical roles of CDT in C. jejuni-induced pathogenesis, including
cell adhesion, invasion, and inflammation. Bacteria that cause
persistent infections associated with chronic inflammatory
responses may possess a high risk of promoting carcinogenesis
(Grivennikov et al., 2010). However, neitherC. jejuni nor its CDT
proteins are associated with malignancies in the gastrointestinal
tract (Brauner et al., 2010). Although rare studies reported CDT
capable of inducing tumorigenesis, CDT-producing Helicobacter
bilis- andH. hepaticus-infectedmice developed colon and hepatic
cancers, respectively (Ericsson et al., 2010; Fox et al., 2011).
These reports revealed a potential correlation between CDT and
carcinogenesis (Guerra et al., 2011). Considering the biological
safety and suitability of developing Cj-CDT as an anticancer
therapeutic agent, in vivo investigation is necessary to determine
the existence of a correlation between chronic infection by CDT-
producing C. jejuni and increases risk of cancer development.
Future investigations focusing on both in vitro and in vivo
models will likely unveil CDT-host interactions at the molecular
level and develop novel strategies to control C. jejuni infection.
The innovative technologies developed because of this research
will enable utilization of this genotoxin as a cancer therapeutic
agent.
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